“…If so and based on previous findings by others showing that testosterone increases insulin secretion (More, Mishra, Hankins, et al., 2016; Morimoto et al., 2001, 2005; Ramaswamy et al., 2016), we thought it possible that flutamide, an AR antagonist, would attenuate the plasma insulin in response to separation and hypoxia and possibly improve insulin sensitivity. Furthermore, we might expect reciprocal changes in plasma glucose due to the flutamide‐mediated modulation of pancreatic islet cell activity (Harada et al., 2019; Kupreeva et al., 2019). Or, it could be possible that corticosterone‐driven insulin resistance (Dallman et al., 1995; Jimeno et al., 2018; Morakinyo et al., 2019; Strack et al., 1995; Tadaishi et al., 2018) could increase plasma glucose which would then stimulate the release in insulin, and that this could be modulated by AR blockade.…”